Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study

Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study

Sentinel lymph node biopsy (SLN) has replaced lymphadenectomy in staging of endometrial carcinoma. The aims of the study were to explore the prevalence of self-reported lymphedema (LEL), identify factors associated with LEL, compare quality of life (QoL) scores using thresholds of clinical importanc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecologic oncology 2023-08, Vol.175, p.72-80
Hauptverfasser: Bjerre Trent, Pernille K., Nordskar, Nina Jebens, Wangen, Knut R., Engeskaug, Ms. Ida, Opheim, Ms. Linn Ø., Aune, Guro, Staff, Anne Cathrine, Thorsen, Lene, Falk, Ragnhild S., Eriksson, Ane Gerda Z.
Format: Artikel
Sprache:eng
Schlagworte:
Cross-Sectional Studies
Endometrial Neoplasms - pathology
EORTC
EQ-5D-5L
Female
Gynecologic Cancer
Humans
Lower Extremity - pathology
Lymph Node Excision - adverse effects
Lymphedema - epidemiology
Lymphedema - etiology
Lymphedema - surgery
Patient reported outcomes measures
Quality of Life
Self Report
Sentinel Lymph Node Biopsy - adverse effects
Surgery
Survivorship
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Sentinel lymph node biopsy (SLN) has replaced lymphadenectomy in staging of endometrial carcinoma. The aims of the study were to explore the prevalence of self-reported lymphedema (LEL), identify factors associated with LEL, compare quality of life (QoL) scores using thresholds of clinical importance, and assess correlation between different questionnaires. Women who underwent staging for endometrial carcinoma from 2006 to 2021 were invited to complete the Lower Extremity Lymphedema Screening Questionnaire (LELSQ), EORTC QLQ-C30, QLQ-EN24 and EQ-5D-5L. Of 2156 invited survivors, 61% participated in the study, whereof 1127 were evaluable by LELSQ. The LEL prevalence was 51%, 36% and 40% after lymphadenectomy, SLN and hysterectomy, respectively (p 
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2023.05.070